Bank Of America

US bank stocks face their longest weekly losing streak since 2008, dropping 11% since September despite solid third-quarter earnings and stable loan performance.

Goldman Sachs maintains its S&P 500 target at 8,000 despite AI bubble fears and tech stock volatility. Analysts stress that earnings growth will drive markets forward.

Major US banks, including Citigroup and Bank of America, are restricting AI agents from customer accounts to prevent billions in deposit outflows to higher-yielding alternatives.

Bank of America global strategist Haim Israel predicts the AI singularity within three years, citing zero-cost intelligence, multi-agent systems, and upcoming AGI breakthroughs.

Bank of America warns investors to monitor two key indicators signalling a potential shift to Risk Off, as bond volatility surges and financial stocks weaken despite overall market resilience.

GitLab shares surged 34.9% in August as AI disruption fears eased. The software firm beat fiscal Q2 expectations with $286.3 million in revenue and a 16% increase in remaining performance obligations.

Bank of America has published a list of stocks with a "buy" rating that it believes are entering September with business tailwinds - including a chip equipment manufacturer, a consumer goods company, and the stock that owns an NBA champion. But the very stock presented as the star of the list also receives a warning. What is hidden behind the recommendations?

The cloud company founded by Israeli-Russian entrepreneur Arkady Volozh published quarterly results that beat forecasts, and the American bank maintains a buy recommendation. The stock has already jumped over 200% since the beginning of the year, but analysts are convinced there is still room to grow.

The investment bank gave Leumi a 'buy' recommendation and expects a 24% upside for the stock compared to its closing price yesterday. 'Revenue momentum has improved, the bank's efficiency has reached new record levels, and credit growth has already reached management's targets for the current year,' the economists wrote.

Bank of America spends over $250 million annually to fund GLP-1 weight-loss medications for its staff. CEO Brian Moynihan views the expenditure as a valuable investment in employee health and well-being.

The Dutch company's stock lost almost 11% in two days amid fears of a new Chinese competitor. Bank of America is convinced the market overreacted, maintaining a "buy" recommendation and pointing to a target that suggests a potential jump of more than 70%.